Immunohistochemical quantification of the vitamin B12 transport protein (TCII), cell surface receptor (TCII-R) and Ki-67 in human tumor xenografts

Anticancer Research

Volumn 33, Issue 10, 2013, Pages 4203-4212

  Sysel, Annette M ^a   Valli, Victor E ^b   Nagle, Ray B ^c   Bauer, Joseph A ^a  

^a Akron Innovation Campus   (United States)

^b VDX VETERINARY DIAGNOSTICS   (United States)

^c UNIVERSITY OF ARIZONA   (United States)

Author keywords

Immunohistochemistry; Ki 67; Receptor; Transcobalamin II; Transport protein; Vitamin B12; Xenograft

Indexed keywords

CD320 ANTIBODY; CELL ANTIBODY; CELL SURFACE RECEPTOR; KI 67 ANTIGEN; MONOCLONAL ANTIBODY KI 67; TCN2 ANTIBODY; TRANSCOBALAMIN II; TRANSCOBALAMIN II RECEPTOR; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATIONAL STUDY; DIGITAL IMAGING; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; PILOT STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; TISSUE MICROARRAY; TISSUE SECTION; TUMOR XENOGRAFT;

IMMUNOHISTOCHEMISTRY; KI-67; RECEPTOR; TRANSCOBALAMIN II; TRANSPORT PROTEIN; VITAMIN B12; XENOGRAFT;

ANIMALS; CELL LINE, TUMOR; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; MICE, SCID; NEOPLASM TRANSPLANTATION; RECEPTORS, CELL SURFACE; TRANSCOBALAMINS; TUMOR MARKERS, BIOLOGICAL;

EID: 84891359260     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (86)

1. Rickes EL, Brink NG, Koniuszy FR et al: Crystalline Vitamin B12. Science 107(2781): 396-397, 1948.
2. Linnell JC and Matthews DM: Cobalamin metabolism and its clinical aspects. Clin Sci (Lond) 66(2): 113-121, 1984.
3. Seetharam B, Bose S, and Li N: Cellular import of cobalamin (Vitamin B-12). J Nutr 129(10): 1761-1764, 1999.
4. Weir DG and Scott JM: Vitamin B12 "cobalamin". In: Modern Nutrition in Health and Disease. Shils ME, Olseon JA, Shike M and Ross AC (eds.). Baltimore, Lippincott Williams & Wilkins, pp. 447-458, 1999.
5. Seetharam B and Li N: Transcobalamin II and its cell surface receptor. Vitam Horm 59: 337-366, 2000.
6. Seetharam B and Yammani RR: Cobalamin transport proteins and their cell-surface receptors. Expert Rev Mol Med 5(18): 1-18, 2003.
7. Rabinowitz R, Rachmilewitz B, Rachmilewitz M et al: Production of transcobalamin II by various murine and human cells in culture. Isr J Med Sci 18(7): 740-745, 1982.
8. Hall CA, Green-Colligan PD, and Begley JA: Synthesis of transcobalamin II by cultured human hepatocytes. Biochim Biophys Acta 838(3): 387-389, 1985.
9. Schohn H, Gueant JL, Girr M et al: Synthesis and secretion of a cobalamin-binding protein by HT 29 cell line. Biochem J 280(Pt 2): 427-430, 1991.
10. Lindemans J, Kroes AC, van Geel J et al: Uptake of transcobalamin II-bound cobalamin by HL-60 cells: effects of differentiation induction. Exp Cell Res 184(2): 449-460, 1989.
11. Amagasaki T, Green R and Jacobsen DW: Expression of transcobalamin II receptors by human leukemia K562 and HL-60 cells. Blood 76(7): 1380-1386, 1990.
12. Bauer JA, Morrison BH, Grane RW et al: Effects of interferon beta on transcobalamin II-receptor expression and antitumor activity of nitrosylcobalamin. J Natl Cancer Inst 94(13): 1010-1019, 2002.
13. Russell-Jones G, McTavish K, McEwan J et al: Vitamin-mediated targeting as a potential mechanism to increase drug uptake by tumours. J Inorg Biochem 98(10): 1625-1633, 2004.
14. Russell-Jones G, McTavish K, and McEwan J: Preliminary studies on the selective accumulation of vitamin-targeted polymers within tumors. J Drug Target 19(2): 133-139, 2011.
15. Ruiz-Sanchez P, Konig C, Ferrari S et al: Vitamin B12 as a carrier for targeted platinum delivery: in vitro cytotoxicity and mechanistic studies. J Biol Inorg Chem 16(1): 33-44, 2011.
16. Collins DA, Hogenkamp HP, O'Connor MK et al: Biodistribution of radiolabeled adenosylcobalamin in patients diagnosed with various malignancies. Mayo Clin Proc 75 (6): 568-580, 2000.
17. Zee-Cheng RK and Cheng CC: Delivery of anticancer drugs. Methods Find Exp Clin Pharmacol 11(7-8): 439-529, 1989.
18. Duncan R: Drug-polymer conjugates: potential for improved chemotherapy. Anticancer Drugs 3(3): 175-210, 1992.
19. Bagnato JD, Eilers AL, Horton RA et al: Synthesis and characterization of a cobalamin-colchicine conjugate as a novel tumor-targeted cytotoxin. J Org Chem 69(26): 8987-8996, 2004.
20. Gupta Y, Ganesh N, Kohli DV et al: Development and characterization of doxorubicin bearing vitamin B12 coupled sterically stabilized liposomes for tumor targeting. Current Nanoscience 7(3): 427-235, 2011.
21. Bauer JA: Synthesis, characterization and nitric oxide release profile of nitrosylcobalamin: a potential chemotherapeutic agent. Anticancer Drugs 9(3): 239-244, 1998.
22. Chawla-Sarkar M, Bauer JA, Lupica JA et al: Suppression of NF-kappa B survival signaling by nitrosylcobalamin sensitizes neoplasms to the anti-tumor effects of Apo2L/TRAIL. J Biol Chem 278(41): 39461-39469, 2003.
23. Bauer JA, Lupica JA, Schmidt H et al: Nitrosylcobalamin potentiates the anti-neoplastic effects of chemotherapeutic agents via suppression of survival signaling. PLoS One 2(12): e1313, 2007.
24. Bauer JA, Frye G, Bahr A et al: Anti-tumor effects of nitrosylcobalamin against spontaneous tumors in dogs. Invest New Drugs 28(5): 694-702, 2010.
25. Tang Z, Bauer JA, Morrison B et al: Nitrosylcobalamin promotes cell death via S nitrosylation of Apo2L/TRAIL receptor DR4. Mol Cell Biol 26(15): 5588-5594, 2006.
26. Sysel AM, Horne WI, Steiner JM et al: Serum folate: a pharmacodynamic biomarker of intracellular nitrosylcobalamin activity following intravenous administration in dogs. Anticancer Res 32(10): 4307-4312, 2012.
27. Collins DA, Hogenkamp HP, and Gebhard MW: Tumor imaging via indium 111-labeled DTPA-adenosylcobalamin. Mayo Clin Proc 74(7): 687-691, 1999.
28. Scholzen T and Gerdes J: The Ki-67 protein: from the known and the unknown. J Cell Physiol 182(3): 311-322, 2000.
29. Gerdes J, Lemke H, Baisch H et al: Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol 133(4): 1710-1715, 1984.
30. Ohsie SJ, Sarantopoulos GP, Cochran AJ et al: Immunohistochemical characteristics of melanoma. J Cutan Pathol 35(5): 433-444, 2008.
31. Heeran MC, Hogdall CK, Kjaer SK et al: Prognostic value of tissue protein expression levels of MIB-1 (Ki-67) in Danish ovarian cancer patients. From the 'MALOVA' ovarian cancer study. APMIS April 18: Epub ahead of print, 2013.
32. Kim BH, Bae YS, Kim SH et al: Usefulness of Ki-67 (MIB-1) immunostaining in the diagnosis of pulmonary sclerosing hemangiomas. APMIS 121(2): 105-110, 2013.
33. Remes SM, Tuominen VJ, Helin H et al: Grading of neuroendocrine tumors with Ki-67 requires high-quality assessment practices. Am J Surg Pathol 36(9): 1359-1363, 2012.
34. Canlorbe G, Laas E, Bendifallah S et al: Contribution of immunohistochemical profile in assessing histological grade of endometrial cancer. Anticancer Res 33(5): 2191-2198, 2013.
35. Nadler A, Cukier M, Rowsell C et al: Ki-67 is a reliable pathological grading marker for neuroendocrine tumors. Virchows Arch 462(5): 501-505, 2013.
36. Li Y, Yang QX, Tian XT et al: Malignant transformation of nasal chondromesenchymal hamartoma in adult: a case report and review of the literature. Histol Histopathol 28 (3): 337-344, 2013.
37. Colleoni M, Rotmensz N, Maisonneuve P et al: Prognostic role of the extent of peritumoral vascular invasion in operable breast cancer. Ann Oncol 18(10): 1632-1640, 2007.
38. Ladstein RG, Bachmann IM, Straume O et al: Ki-67 expression is superior to mitotic count and novel proliferation markers PHH3, MCM4 and mitosin as a prognostic factor in thick cutaneous melanoma. BMC Cancer 10: 140, 2010.
39. Gasparini G, Pozza F, Meli S et al: Breast cancer cell kinetics: immunocytochemical determination of growth fractions by monoclonal antibody Ki-67 and correlation with flow cytometric S-phase and with some features of tumor aggressiveness. Anticancer Res 11(6): 2015-2021, 1991.
40. Bader AA, Tio J, Petru E et al: T1 breast cancer: identification of patients at low risk of axillary lymph node metastases. Breast Cancer Res Treat 76(1): 11-17, 2002.
41. Margulis V, Shariat SF, Ashfaq R et al: Ki-67 is an independent predictor of bladder cancer outcome in patients treated with radical cystectomy for organ-confined disease. Clin Cancer Res 12(24): 7369-7373, 2006.
42. Miyake H, Sakai I, Muramaki M et al: Prediction of response to combined immunotherapy with interferon-alpha and low-dose interleukin-2 in metastatic renal cell carcinoma: expression patterns of potential molecular markers in radical nephrectomy specimens. Int J Urol 16 (5): 465-471, 2009.
43. Takei H, Kurosumi M, Yoshida T et al: Neoadjuvant endocrine therapy of breast cancer: which patients would benefit and what are the advantages? Breast Cancer 18(2): 85-91, 2011.
44. Lazzeroni M, Guerrieri-Gonzaga A, Botteri E et al: Tailoring treatment for ductal intraepithelial neoplasia of the breast according to Ki-67 and molecular phenotype. Br J Cancer 108(8): 1593-1601, 2013.
45. Mao JT, Roth MD, Fishbein MC et al: Lung cancer chemoprevention with celecoxib in former smokers. Cancer Prev Res (Phila) 4 (7): 984-993, 2011.
46. Dede DS, Gumuskaya B, Guler G et al: Evaluation of changes of biologic markers ER, PR, HER 2 and Ki-67 in breast cancer with administration of neoadjuvant dose-dense doxorubicin, cyclophosphamide followed by paclitaxel. J BUON 18(1): 57-63, 2013.
47. Brandao RD, Veeck J, Van de Vijver KK et al: A randomised controlled phase II trial of pre-operative celecoxib treatment reveals anti-tumour transcriptional response in primary breast cancer. Breast Cancer Res 15(2): R29, 2013.
48. Fisher G, Yang ZH, Kudahetti S et al: Prognostic value of Ki-67 for prostate cancer death in a conservatively managed cohort. Br J Cancer 108(2): 271-277, 2013.
49. Reyal F, Hajage D, Savignoni A et al: Long-term prognostic performance of Ki67 rate in early stage, pT1-pT2, pN0, invasive breast carcinoma. PLoS One 8 (3): e55901, 2013.
50. Sanchez-Munoz A, Plata-Fernandez YM, Fernandez M et al: The role of immunohistochemistry in breast cancer patients treated with neoadjuvant chemotherapy: an old tool with an enduring prognostic value. Clin Breast Cancer 13(2): 146-152, 2013.
51. Wang Y, Yin Q, Yu Q et al: A retrospective study of breast cancer subtypes: the risk of relapse and the relations with treatments. Breast Cancer Res Treat 130(2): 489-498, 2011.
52. Yamashita S, Moroga T, Tokuishi K et al: Ki-67 labeling index is associated with recurrence after segmentectomy under video-assisted thoracoscopic surgery in stage I non-small cell lung cancer. Ann Thorac Cardiovasc Surg 17(4): 341-346, 2011.
53. Ramirez C, Cheng S, Vargas G et al: Expression of Ki-67, PTTG1, FGFR4, and SSTR 2, 3, and 5 in nonfunctioning pituitary adenomas: a high throughput TMA, immunohistochemical study. J Clin Endocrinol Metab 97 (5): 1745-1751, 2012.
54. Li R, Heydon K, Hammond ME et al: Ki-67 staining index predicts distant metastasis and survival in locally advanced prostate cancer treated with radiotherapy: an analysis of patients in radiation therapy oncology group protocol 86-10. Clin Cancer Res 10(12 Pt 1): 4118-4124, 2004.
55. Gimotty PA, Van Belle P, Elder DE et al: Biologic and prognostic significance of dermal Ki67 expression, mitoses, and tumorigenicity in thin invasive cutaneous melanoma. J Clin Oncol 23(31): 8048-8056, 2005.
56. Lusby K, Savannah KB, Demicco EG et al: Uterine leiomyosarcoma management, outcome, and associated molecular biomarkers: A single institution's experience. Ann Surg Oncol 20 (7): 2364-2372, 2013.
57. Dunstan RW, Wharton KA Jr., Quigley C et al: The use of immunohistochemistry for biomarker assessment - can it compete with other technologies? Toxicol Pathol 39(6): 988-1002, 2011.
58. Lehr HA, Mankoff DA, Corwin D et al: Application of photoshop-based image analysis to quantification of hormone receptor expression in breast cancer. J Histochem Cytochem 45(11): 1559-1565, 1997.
59. Bhatnagar J, Tewari HB, Bhatnagar M et al: Comparison of carcinoembryonic antigen in tissue and serum with grade and stage of colon cancer. Anticancer Res 19(3B): 2181-2187, 1999.
60. Helps SC, Thornton E, Kleinig TJ et al: Automatic nonsubjective estimation of antigen content visualized by immunohistochemistry using color deconvolution. Appl Immunohistochem Mol Morphol 20(1): 82-90, 2012.
61. Podhajsky RJ, Bidanset DJ, Caterson B et al: A quantitative immunohistochemical study of the cellular response to crush injury in optic nerve. Exp Neurol 143(1): 153-161, 1997.
62. Dias P, Chen B, Dilday B et al: Strong immunostaining for myogenin in rhabdomyosarcoma is significantly associated with tumors of the alveolar subclass. Am J Pathol 156(2): 399-408, 2000.
63. Jacobs JJ, Lehe C, Cammans KD et al: An automated method for the quantification of immunostained human Langerhans cells. J Immunol Methods 247(1-2): 73-82, 2001.
64. Bloom K and Harrington D: Enhanced accuracy and reliability of HER-2/neu immunohistochemical scoring using digital microscopy. Am J Clin Pathol 121 (5): 620-630, 2004.
65. Lopez C, Lejeune M, Salvado MT et al: Automated quantification of nuclear immunohistochemical markers with different complexity. Histochem Cell Biol 129(3): 379-387, 2008.
66. Tuominen VJ, Ruotoistenmaki S, Viitanen A et al: ImmunoRatio: a publicly available web application for quantitative image analysis of estrogen receptor (ER), progesterone receptor (PR), and Ki-67. Breast Cancer Res 12(4): R56, 2010.
67. Lejeune M, Jaen J, Pons L et al: Quantification of diverse subcellular immunohistochemical markers with clinicobiological relevancies: validation of a new computer-assisted image analysis procedure. J Anat 212(6): 868-878, 2008.
68. Schneider CA, Rasband WS, and Eliceiri KW: NIH Image to ImageJ: 25 years of image analysis. Nat Methods 9(7): 671-675, 2012.
69. Ruifrok AC and Johnston DA: Quantification of histochemical staining by color deconvolution. Anal Quant Cytol Histol 23 (4): 291-299, 2001.
70. Landini G: Color deconvolution using ImageJ. 2013: URL http://www.dentistry.bham.ac.uk/landinig/software/software.html
71. Vrekoussis T, Chaniotis V, Navrozoglou I et al: Image analysis of breast cancer immunohistochemistry-stained sections using ImageJ: an RGB-based model. Anticancer Res 29(12): 4995-4998, 2009.
72. Safadi RA, Musleh AS, Al-Khateeb TH et al: Analysis of immunohistochemical expression of k19 in oral epithelial dysplasia and oral squamous cell carcinoma using color deconvolution-image analysis method. Head Neck Pathol 4(4): 282-289, 2010.
73. Hirano H, Yonezawa H, Yunoue S et al: Immunoreactivity of Wnt5a, Fzd2, Fzd6, and Ryk in glioblastoma: evaluative methodology for DAB chromogenic immunostaining. Brain Tumor Pathol June 9: Epub ahead of print, 2013.
74. Taylor CR and Levenson RM: Quantification of immunohistochemistry - issues concerning methods, utility and semiquantitative assessment II. Histopathology 49(4): 411-424, 2006.
75. Walker RA: Quantification of immunohistochemistry - issues concerning methods, utility and semiquantitative assessment I. Histopathology 49(4): 406-410, 2006.
76. Dowsett M, Nielsen TO, A'Hern R et al: Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group. J Natl Cancer Inst 103(22): 1656-1664, 2011.
77. Hall CA: The uptake of vitamin B12 by human lymphocytes and the relationships to the cell cycle. J Lab Clin Med 103(1): 70-81, 1984.
78. Fiskerstrand T, Riedel B, Ueland PM et al: Disruption of a regulatory system involving cobalamin distribution and function in a methionine-dependent human glioma cell line. J Biol Chem 273 (32): 20180-20184, 1998.
79. Abe T, Tada M, Shinohara N et al: Establishment and characterization of human urothelial cancer xenografts in severe combined immunodeficient mice. Int J Urol 13(1): 47-57, 2006.
80. Flatmark K, Reed W, Halvorsen T et al: Pseudomyxoma peritonei - two novel orthotopic mouse models portray the PMCA-I histopathologic subtype. BMC Cancer 7: 116, 2007.
81. Stoyanova R, Hachem P, Hensley H et al: Antisense-MDM2 sensitizes LNCaP prostate cancer cells to androgen deprivation, radiation, and the combination in vivo. Int J Radiat Oncol Biol Phys 68 (4): 1151-1160, 2007.
82. Fatema CN, Zhao S, Zhao Y et al: Monitoring tumor proliferative response to radiotherapy using (18)F-fluorothymidine in human head and neck cancer xenograft in comparison with Ki-67. Ann Nucl Med 27(4): 355-362, 2013.
83. Schneider RJ, Burger RL, Mehlman CS et al: The role and fate of rabbit and human transcobalamin II in the plasma transport of vitamin B12 in the rabbit. J Clin Invest 57(1): 27-38, 1976.
84. Youngdahl-Turner P, Mellman IS, Allen RH et al: Protein mediated vitamin uptake. Adsorptive endocytosis of the transcobalamin II-cobalamin complex by cultured human fibroblasts. Exp Cell Res 118(1): 127-134, 1979.
85. Fasanella S, Leonardi E, Cantaloni C et al: Proliferative activity in human breast cancer: Ki-67 automated evaluation and the influence of different Ki-67 equivalent antibodies. Diagn Pathol 6(Suppl 1): S7, 2011.
86. Pathmanathan N and Balleine RL: Ki67 and proliferation in breast cancer. J Clin Pathol 66(6): 512-516, 2013.